Transitional cell carcinoma epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Transitional cell carcinoma}} | {{Transitional cell carcinoma}} | ||
{{CMG}} | |||
==Overview== | |||
==Epidemiology and Demographics== | |||
Transitional cell carcinoma of the renal pelvis, accounting for only 7% of all kidney tumors, and transitional cell cancer of the ureter, accounting for only 1 of every 25 upper tract tumors, are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or ureter. Patients with deeply invasive tumors that are still confined to the renal pelvis or ureter have a 10% to 15% likelihood of cure. Patients with tumors with penetration through the urothelial wall or with distant metastases usually cannot be cured with currently available forms of treatment.<ref name= NIH>Transitional cell cancer. National cancer institute. http://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq#section/_1</ref> | |||
==References== | ==References== | ||
Revision as of 14:41, 10 February 2016
|
Transitional cell carcinoma Microchapters |
|
Differentiating Transitional cell carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Transitional cell carcinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Transitional cell carcinoma epidemiology and demographics |
|
FDA on Transitional cell carcinoma epidemiology and demographics |
|
CDC on Transitional cell carcinoma epidemiology and demographics |
|
Transitional cell carcinoma epidemiology and demographics in the news |
|
Blogs on Transitional cell carcinoma epidemiology and demographics |
|
Directions to Hospitals Treating Transitional cell carcinoma |
|
Risk calculators and risk factors for Transitional cell carcinoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Epidemiology and Demographics
Transitional cell carcinoma of the renal pelvis, accounting for only 7% of all kidney tumors, and transitional cell cancer of the ureter, accounting for only 1 of every 25 upper tract tumors, are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or ureter. Patients with deeply invasive tumors that are still confined to the renal pelvis or ureter have a 10% to 15% likelihood of cure. Patients with tumors with penetration through the urothelial wall or with distant metastases usually cannot be cured with currently available forms of treatment.[1]
References
- ↑ Transitional cell cancer. National cancer institute. http://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq#section/_1